Dr Reddy’s Laboratories says Brazil’s medicines regulator ANVISA has approved its generic semaglutide injection, clearing the company to market and sell the once-weekly treatment for adults with type 2 diabetes whose blood sugar remains inadequately controlled. The medicine is intended to be used alongside diet and exercise, and is supplied in pre-filled pens in 2 mg and 4 mg strengths.

The approval comes after ANVISA previously rejected Dr Reddy’s application in April. Both outlets frame the decision as part of Dr Reddy’s international expansion, positioning generic semaglutide as a growth driver in diabetes-focused markets. The first article also notes semaglutide’s link to Novo Nordisk’s Ozempic (and Wegovy for weight management), and adds that Dr Reddy’s is preparing other regional launches, including a relaunch in Canada and additional planned entries across Latin America and Africa. The second outlet adds that Dr Reddy’s plans to launch in Brazil with partner Aché, highlighting the scale of the addressable market it expects to tap.